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Materials and Methods 
 
Exome sequencing of 3222 Pakistani-heritage adult individuals living in the UK 
Subjects and phenotypes 
Birmingham adult Pakistani-heritage subjects comprised 130 subjects from a Birth 
Cohort study in Birmingham, UK(27), 471 adult healthy, and 892 adult type 2 diabetes 
subjects from Birmingham and Coventry as part of the UK Asian Diabetes Study(28) - a 
total of 1493 DNA subject samples, resulting in (after all quality control steps) 1060 
exome sequenced subject samples. Approval was from the Birmingham East, North and 
Solihull Research Ethics Committee and from the South Birmingham Research Ethics 
Committee. 
Born in Bradford (BiB) is a longitudinal multi-ethnic birth cohort study aiming to 
examine the impact of environmental, psychological and genetic factors on maternal and 
child health and wellbeing(29, 30). The full BiB cohort recruited 12,453 women during 
13,776 pregnancies between 2007 and 2010. Ethical approval was granted by Bradford 
Research Ethics Committee. BiB adults studied here comprised 2490 DNA subject 
samples from pregnant women (>95% self-stated Pakistani-heritage) ascertained at an 
antenatal clinic visit in Bradford, UK(29), resulting in (after all quality control steps) 
2162 exome sequenced subject samples. The first 1570 samples were of unselected 
parental relatedness status and included 554 with self-stated first cousin parental 
relatedness, the remaining samples were all of self-stated first cousin parental relatedness. 
We deliberately included (before the quality control stage) duplicate samples (taken at 
different antenatal visits for each of multiple pregnancies). We also recalled selected 
subjects for a second sample for genotype validation by a different method. 
 
Exome sequencing and sequence-level quality control 
   Genomic DNA was extracted from peripheral blood, and quality confirmed by 
agarose gel electrophoresis (requiring high molecular weight) and picogreen assay. 
Samples were genotyped for identity checking by either Sequenom (San Diego, USA) 
assay (26 common autosomal variants, and 4 gender markers) or Fluidigm (San 
Francisco, USA) assay (22 common autosomal variants, and 4 gender markers). Samples 
where DNA-based gender and stated gender were mis-matched were excluded. 
   Genomic DNA (approximately 1 ug) was fragmented to an average size of 150 bp 
and subjected to DNA library creation using established Illumina paired-end protocols. 
Adapter-ligated libraries were amplified and indexed via PCR. A portion of each library 
was used to create an equimolar pool comprising 8 indexed libraries. Each pool was 
hybridised to SureSelect RNA baits (Human All Exon V5, Agilent Technologies, Santa 
Clara, USA) and sequence targets were captured and amplified in accordance with 
manufacturer’s recommendations. Enriched libraries were used for 75 base paired-end 
sequencing (HiSeq 2000, Illumina, San Diego, USA) following manufacturer’s 
instructions. Sequencing was performed to an expected ~40x read-depth, since the 
primary aim was to identify homozygous genotypes in autozygous regions. 
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Sample filtering 
   Stated duplicates were obtained from the BiB cohort, which took repeat samples 
when the same individuals registered at the Bradford hospital maternity ward for multiple 
pregnancies. A total of 149 individuals who registered for 2 pregnancies and 4 
individuals who had registered for 3 pregnancies were recorded. From these duplicate 
pairings a total of 153 pairs had sequence data. Duplicate checks were performed using 
bcftools (version: 1.1-113-gd991f3f used throughout) gtcheck -G1 to compute the 
pairwise discordance between samples. 1000 random bi-allelic SNP sites were chosen out 
of a set of markers that were of at least MAF>0.05 in both the BiB dataset as well as the 
1000 Genomes Project Phase3 release set, and had at least a mean sequencing depth of 
20. Duplicates could be clearly separated from other samples based on number of 
discordant genotypes between each pair of sample. A duplicate sample was then removed 
from each pair so that there were unique samples for subsequent analyses. 
   To confirm sample identity and exclude laboratory mix-ups we compared the 
genotype calls made using Sequenom or Fluidigm as described above with those from 
our sequencing data. We removed 30 samples for which there was a genotype 
discordance of more than 30%. 
   Principal components analysis (PCA) to determine individual ethnicity was 
performed by merging bi-allelic SNPs from the current dataset with the 1000 Genomes 
Project phase 3 release set. Bi-allelic SNP sites that were of at least MAF>0.05 in each of 
the datasets were taken to define a set of markers used to perform the PCA analysis. PCA 
was first performed with 1000 Genomes Project data using all populations, and samples 
from the current dataset projected onto that reference. Pakistani-heritage subjects could 
clearly be defined, distinct from other South Asian ancestries on component 2 and 3 of 
the PCA and a region of the plot containing the majority of the samples was defined, 
leading to the removal of 294 samples that plotted outside the region (fig. S2). These 294 
contained 20 samples with a 10-fold enrichment in the number of singleton sites which 
support ancestry other than the main cohort of British Pakistani subjects. Finally, using 
VerifyBamID(31) (freemix parameter > 0.03), we removed 24 samples that were 
predicted to have contamination between the samples. 
 
Alignment and BAM processing 
   Following generation of raw reads, these were converted to BAM format using 
illumina2BAM and lanes de-multiplexed so that the tags were isolated from the body of 
the read, decoded, and used to separate out each lane into lanelets containing individual 
samples from the multiplex library and the PhiX control. Reads corresponding to the 
PhiX control were mapped and used with WTSI's spatial filter program to identify reads 
from other lanelets that contained spatially oriented INDEL artefacts and mark them as 
QC fail. Reads were aligned with BWA-MEM to the GRCh37+decoy reference genome 
used by the 1000 Genomes project 
(ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/reference/phase2_reference_assembly
_sequence/hs37d5.fa.gz). PCR and optically duplicated reads were marked using Picard 
MarkDuplicates, and after manual QC passing data was deposited with the EBI-EGA. 
   In order to ensure the quality of the large quantity of BAMs produced for the 
project, an automated quality control system was employed to reduce the number of data 
files that required manual intervention. This system was derived from the one originally 
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designed for the UK10K project(14) and used a series of empirically derived thresholds 
to assess summary metrics calculated from the input BAMs. These thresholds included: 
percentage of reads mapped; percentage of duplicate reads marked; various statistics 
measuring indel distribution against read cycle and an insert size overlap percentage. Any 
lane that fell below the "fail" threshold for any of the metrics were excluded; any lane 
that fell below the "warn" threshold on a metric would be manually examined; and any 
lane that did not fall below either of these thresholds for any of the metrics was given a 
status of "pass" and allowed to proceed into the later stages of the pipeline. 
   Passed lanelets were then merged into BAMs corresponding to sample's libraries 
and duplicates were marked again with Picard after which they were then merged into 
BAMs for each sample. Next, for each sample we re-aligned reads around known and 
discovered indels followed by base quality score recalibration using GATK (version: 
v3.3-0 used throughout). Lastly samtools ‘calmd’ was applied and indexes were created. 
Known indels for realignment were taken from Mills-Devine(32) and 1000 Genomes 
Project Phase 1(33) low coverage set, available from the 1000 Genomes ftp site. Known 
variants for base quality score recalibration were taken from dbSNP 137. 
 
Variant calling 
   Two variant call-sets, one with the Genome Analysis Toolkit(34, 35) (GATK) 
HaplotypeCaller and one with samtools/bcftools(36), were made from the 4,353 samples 
that passed QC measures to this point. Calling was restricted to the Agilent V5 exome 
bait regions +/- a 100bp window on either end. The following parameters were used: 
 
GATK HaplotypeCaller [GATK version: v3.3-0]: 
Single-sample genome VCF (gVCF) files were created using GATK 
HaplotypeCaller run in gVCF mode on each of the sample BAM files using parameters: 
 -T HaplotypeCaller -R hs37d5.fa -variant_index_type LINEAR -
variant_index_parameter 128000 
    --disable_auto_index_creation21478889_and_locking_when_reading_rods --
minPruning 3 
    --maxNumHaplotypesInPopulation 200 -ERC GVCF --max_alternate_alleles 3 -
contamination 0.0 
 -L 
Agilent_human_exome_v5_S04380110/S04380110_Covered.baits.nochr.w100.nr.bed 
For each chromosome, we ran CombineGVCFs in batches of ~65 samples using 
parameters: 
 -T CombineGVCFs -R hs37d5.fa --
disable_auto_index_creation_and_locking_when_reading_rods 
 --variant sample1.vcf.gz --variant sample2.vcf.gz ... -isr INTERSECTION 
 -L $chr -L 
Agilent_human_exome_v5_S04380110/S04380110_Covered.baits.nochr.w100.nr.bed 
Then, for each chromosome, we ran GenotypeGVCFs on the output of 
CombineGVCFs using parameters: 
 -T GenotypeGVCFs -R hs37d5.fa --
disable_auto_index_creation_and_locking_when_reading_rods 
 --variant group1.vcf.gz --variant group2.vcf.gz ... -isr INTERSECTION 
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 -L $chr -L 
Agilent_human_exome_v5_S04380110/S04380110_Covered.baits.nochr.w100.nr.bed 
 
SAMtools/BCFtools: [samtools version: 1.1-30-g7f47a7c, bcftools version: 1.1-113-
gd991f3f, htslib version: 1.1-104-g948a68c]:  
All-site, all-sample BCF files from all the BAM files were generated using 
`samtools mpileup`. This processing was split into 100Mb chunks across the genome 
using parameters: 
   samtools mpileup -t DP,DPR,INFO/DPR -C50 -pm3 -F0.2 -d2000 -L500 \ 
   -l 
Agilent_human_exome_v5_S04380110/S04380110_Covered.baits.nochr.w100.nr.bed \ 
   -g -r $chr:$from-$to -b $bam_list -f hs37d5.fa > $chr:$from-$to.bcf 
For each chunk, variants were called using `bcftools call` using parameters: 
   bcftools call -vm -f GQ $chr:$from-$to.bcf | bgzip -c > $chr:$from-$to.vcf.gz 
On chromosome X, male samples were treated as diploid in the pseudo-autosomal 
regions (X:60001-2699520 and X:154931044-155270560) and haploid otherwise using 
the `-X' option in `bcftools call`. 
 
   From the two initial callsets produced using GATK and samtools, we created a 
consensus call-set by intersecting the set of bi-allelic sites produced by each caller. The 
concordance between the two call-sets for SNPs was 95%, discordant genotypes were set 
to missing, variants with >1% missing genotypes were excluded, and all subsequent 
analyses performed on this consensus call-set. The ratio of transitions to transversions 
(Ts/Tv) in the consensus call-set was 2.52 for all variants and 2.42 for singletons (37.3% 
of SNPs), with much lower Ts/Tv ratios for discordant calls. 
We did not attempt to identify large deletions (e.g. >100bp) in our dataset, as these 
methods remain inaccurate for medium depth sequencing (the ~40x depth used here for 
most samples); we note that as a consequence we will have called a hemizygous LOF 
genotype (with the other allele a deletion) as a homozygote, but that this would still lead 
to complete allelic inactivation. 
 
Estimating variant quality 
   Estimation of error rates in exome sequencing data typically includes comparison 
with different technologies, or pedigree analysis, which whilst effective may miss 
systematic errors. A recent study(37) used a haploid human cell line, reporting 
heterozygous calls in the data as a proxy for error rate. Here, we use a similar strategy by 
examining the number of heterozygous calls within long autozygous stretches in our final 
call-set of 3222 Pakistani-heritage adults. We expect that long stretches of >10Mb 
autozygosity have occurred due to a recent inbreeding event, and therefore we can 
attribute heterozygous calls within such regions to either a de-novo mutation/gene 
conversion event, or a sequencing error. As the regions of autozygosity across these 
individuals occur due to random recombination events, we are able to measure errors 
occurring on multiple haplotypes and on joint called data. 
We restricted autozygous regions considered to those at least 10Mb long and with 
no other region in that individual starting within 3Mb, and excluding the terminal 1Mb of 
each autozygous region. These stretches are long (often comprising a fifth of an entire 
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chromosome) and heterozygous calls within them are equally likely to be seen in the 
middle of such stretches as compared to the ends (t-test P=0.74). Overall we saw 88192 
heterozygote calls in 12676437517bp of autozygous callable exome sequence, a rate of 
less than 1 per 100,000bp.  Downsampled to the length of a single genome, this amounts 
to 19831 false heterozygotes per genome, within the range previously reported of 15000–
30000 false heterozygotes per haploid genome sequenced at high coverage without PCR 
artifacts(38).  This is still much higher than the expected rate due to new mutations, 
which is approximately 10-7 per bp (6 generations at a mutation rate of 1.5*10-8 per bp 
per generation), so most heterozygote calls within the autozygous sections are due to 
errors.  
  
Final variant filtering 
   We next used the Variant Quality Score Recalibration (VQSR) tool within GATK 
to calibrate the probability of variant call error, and further filter the dataset based on this 
single estimate for the accuracy of each call. We trained the VariantRecalibrator 
Gaussian mixture model using a set of true sites from HapMap project variants(35). We 
used the following metrics to train the model - for SNPS: QD, FS, MQRankSum, 
ReadPosRankSum, BaseQRankSum, MQ, InbreedingCoeff, SOR, GQ_MEAN, NCC; 
and for indels QD, FS, ReadPosRankSum, BaseQRankSum, MQ, InbreedingCoeff, SOR, 
GQ_MEAN, NCC. After calibrating using the heterozygotes in autozygous regions 
identified above as false positives (fig. S5), we chose the VQSR 99% filtering threshold 
for SNPs, and no VQSR filtering on the indels (VQSR did not increase specificity for 
indels). We used this as the final dataset reported in the main results section of this paper. 
In this final dataset, the SNP heterozygous call error rate is 1.47% (the rate of false 
heterozygote calls in autozygous regions as a fraction of the total rate of heterozyote calls 
in non-autozygous regions) and the corresponding indel heterozygous call error rate was 
1.63%. The ratio of transitions to transversions (Ts/Tv) in the final call-set was 2.56 for 
all variants and 2.50 for singletons.  
   As an additional method to estimate error rate, we used 176 pairs of known 
duplicate samples (independent blood samples taken from Born In Bradford mothers at 
separate pregnancies). By examining the replication rate of heterozygous calls within 
autozygous sections in these individuals, we can classify our calls into those that are 
concordant; those likely to be due to systematic reasons (such as read mis-alignment to 
the genome, or de novo mutations) and those that are discordant; which are likely to be 
due to random issues in the sequencing process or sampling of reads during variant 
calling. For SNPs, there were on average approximately 27500 homozygous alternate 
calls/individual of which 1650 were in autozygous regions, with 99.25% replication in 
duplicate samples (99.6% in autozygous regions). With VQSR at 99% we lost 1.3% of 
these 27500 calls. There was a mean of 20 false heterozygote SNP calls/individual, with 
50.1% replication in duplicate samples. For indels, there were mean 2068 homozygous 
alternate calls per person of which mean 123 were in autozygous regions, with 91.8% 
replication in duplicate samples (92.9% in autozygous regions). There was a mean of 2.6 
false heterozygote indel calls/individual, with 24.8% replication in duplicate samples 
(Table S5).  Using the 176 pairs of duplicate DNA samples from individuals to estimate 
the reproducibility of homozygous alternate allele genotypes in the final call set, we 
found a 0.5% SNP homozygous genotype discordance rate (0.3% within autozygous 
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segments) and a 8.2% indel homozyous genotype discordance rate (7.1% in autozygous 
regions).  
 
 
Functional annotation of variants from exome sequencing 
   Loss-of-function (LOF) annotation was performed using the Loss-Of-Function 
Transcript Effect Estimator (LOFTEE, version 0.2, available at 
https://github.com/konradjk/loftee) a plugin to the Ensembl Variant Effect Predictor 
(VEP, version 77) based on GENCODE version 19 for the GENCODE basic set(39). 
LOFTEE considers all stop-gained, splice-disrupting, and frameshift variants, and filters 
out many known false-positive modes, such as variants near the end of transcripts and in 
non-canonical splice sites, as described in the code documentation. As a variant may have 
multiple different effects on different transcripts, the annotation of function is based on 
the most severe consequence per variant in the order as defined in Ensembl 
(http://www.ensembl.org/info/genome/variation/predicted_data.html). 
   
 
Identification of autozygous genomic segments 
We applied a hidden Markov model (HMM) first utilized in(40) 
(https://samtools.github.io/bcftools/bcftools.html) to identify regions of homozygosity 
(absence of heterozygous variation) due to parental relatedness with the important 
addition of utilising the fine scale sex averaged human recombination map(41). The allele 
frequency information was obtained using all 3,222 exomes and the transition parameters 
between autozygous and non-autozygous sections were learnt from the data using a 
Viterbi training scheme (segmental k-means algorithm), with the initial probabilities of 
being in the N (non-homozygous) or H (homozygous) state at the start of each 
chromosome set to equal. The resulting state assignments given by the Viterbi sequence 
with the optimal parameters comprised our inferred homozygous and non-homozygous 
tracts. All regions of homozygosity identified were >10kb in length.  
The command line used for the inference using bcftools roh was: 
bcftools roh -G30 -a1e-8 -H1e-8 -e - -G30 -V -m 
genetic_map_chr{CHROM}_combined_b37.txt 
 We then compared our estimates of genetic autozygosity with those from self-
stated estimates (fig. S4A). This confirmed our results in two ways. First, the estimate of 
genetic autozygosity corresponded with those from theoretical predictions from pedigree 
data, with offspring with higher parental relatedness having higher autozygosity. Second, 
we found that the median autozygosity from our genomic estimates was elevated over 
what we would expect in otherwise outbred individuals (first cousins, 6.25% and second 
cousins, 3.125%). This can be attributed to longstanding endogamy in the population 
which would lead to additional historic identity by descent. Additionally we noted that 
the variance even within individuals who stated that they were children of first cousins is 
extremely large, with estimates ranging from 0 to 25%. 
After removing artifacts near locations close to the centromeres where we had low 
coverage in the sequencing data, we calculated the number of individuals that are 
autozygous at every site across the genome (fig. S4B), from which we can draw the 
following conclusions.  
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Every position in the genome contains at least one individual who is autozygous at a 
certain site, with a mean of 210. 
The distribution of individuals who are autozygous at a site is not significantly 
different from random (Shapiro-Wilks test, see main text). The expectation was 
calculated by taking a weighted average of the overall inbreeding coefficient of each 
individual and assuming that the distribution of such sections would follow a binomial 
distribution and by approximation normal across 3,222 samples. Furthermore, the fact 
that these segments are randomly located across the genome and that such segments lie in 
hundreds of individuals with differing haplotypes means heterozygote sites can be used 
as a means of quality control of variants without any bias related to genomic location. 
We find that 94.9% of all rhLOFs lie within the identified autozygous sections.  This 
confirms that the overwhelming majority of homozygous genotypes were inherited from 
the parents at conception and hence not mosaics, ruling out mosaicism as a possible 
major reason for incomplete penetrance. 
 
 
Exome Aggregation Consortium (ExAC) and Icelandic population comparisons 
We compared genes containing rhLOF in our dataset versus the genes containing 
homozygous LOF (restricting to high confidence variants including PASS all filters, and 
80% call rate across all samples) in the Exome Aggregation Consortium (ExAC, 
http://exac.broadinstitute.org, data release 0.3 with VEPv79 annotation, accessed June 
2015). A total of 1775 of 26915 genes in ExAC from 60706 individuals contained 
homozygous LOF genotypes. We included variants of all allele frequencies, as ExAC 
comprises multiple diverse ethnicities. 
We compared genes containing rhLOF in our dataset versus the 1,171 genes 
containing homozygous LOF or compound heterozygous LOF for variants with a minor 
allele frequency <2% in the Icelandic sequenced dataset, using both direct sequenced and 
imputed Icelandic population data from 104,220 samples. 
 
 
Expected number of knockout variants to be seen in larger cohorts 
The sequence data obtained from 3,222 healthy individuals provides us with a 
sample of the number and diversity of LOF variants (in both heterozygous and 
homozygous states) available in this specific population and we can use this to obtain 
estimates on the number of knockouts we expect to see in future sequencing up to 
100,000 samples. In 3,222 individuals we observe 6,444 copies of each gene sampled 
from the population. In 100,000 people of first cousin offspring (each individual having 
6.25% identity by descent), we expect to see 6250 homozygosed copies of each gene. 
Since this number is smaller than the number of observed copies (6,444) we could 
downsample the observed data set of haplotypes. As this does not account for 
heterozygous variation that would be incompatible with healthy life when homozygosed, 
we then reduce the estimated number of variant sites seen by 13.7% as this is the 
expected depletion of LOFs estimated using our subsampling approach. We plot the 
results as a function of sample size in fig. S3. We expect these to be conservative 
estimates because we are including the regions that are autozygous in these individuals in 
our initial sampling. Based on this current data we note that there are a large number of 
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genes yet undiscovered in which knockouts are likely to be compatible with adult human 
life, and that the discovery rate of these genes does not appear to plateau even if a study 
were to sequence 100,000 subjects with closely related parents. We also expect different 
sets of variation in different ethnicities and populations. 
 
 
Selection signatures of LOF variants in autozygous and non-autozygous regions. 
    We examined direct selection on recessive deleterious LOF variants by 
comparing the rates at which we observe variant sites of different mutational classes 
within and outside of autozygous tracts within individuals. Since the individuals 
ascertained in this study were healthier adults when sampled, recessive LOF variants that 
lead to death as an embryo, foetus or child, or result in severe early-onset Mendelian 
disease should be less frequent in autozygous tracts, where they are exposed, while still 
present in non-autozygous portions of the genome. To control for the differing amount of 
autozygosity within the individuals as well as any differences in the relative rates of 
diversity inside and outside of autozygous sections, we normalize the total number of 
LOF genotypes seen in each section by the total number of variants in each section. We 
assess significance of the difference between relative rates of variants in the autozygous 
and non-autozygous portions of the genome using a t-test where the autozygous and non-
autozygous rates are paired. To adjust for inconsistencies that might arise due to sampling 
error from individuals with small regions of autozygosity we further restrict our 
comparison to samples that have a total autozygous length of >=5%. We then examine 
the results of this statistic using different classes of variants (fig. 2A). We show as a 
control that rates of synonymous variants are not significantly reduced between the 
autozygous and non-autozygous sections, and then show a significant reduction in the 
rate at which we observe LOF variants within autozygous sections as compared to the 
non-autozygous sections, demonstrating direct selection against highly deleterious 
recessive variants.  
 
 
Quantifying the depletion of LOF genotypes     
The previous analysis on variant genotypes within and outside of autozygous tracts 
suggests that synonymous variants are an effective neutral control, and that there has 
been selection against homozygous LOF variation. In the allele frequency range under 
1% there were 16,163 segregating LOF variants, with >= 1 non-reference homozygote 
genotype (rhLOF) found at 847 variants. We then matched the LOF variants to randomly 
selected synonymous variants with the same allele frequency and observed at how many 
of these variant sites non-reference homozygotes occurred, repeating the random 
selection process 10,000 times to estimate the distribution expected under neutrality. fig. 
2B shows the resulting distributions and variant counts. We see a 13.7% deficit in 
variants containing rhLOF genotypes compared to the mean of the distribution for 
matched synonymous sites. This estimate makes no use of our earlier autozygosity 
assignment, so is not biased by any inaccuracy in autozygosity assignment. It is an 
average over the range of allele frequencies below 1% homozygosed in our sample. 
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The average number of recessive lethal variants carried by humans 
The concept of lethal equivalents, defined as the expected number of heterozygous 
mutations in a single individual that would result in lethality when homozygosed, was 
first introduced in 1956, when it was estimated by a regression of the degrees of parental 
relatedness on the viabilities of their offspring(42). Whist methodologically sound, the 
estimate of the inbreeding coefficient of the infants was obtained theoretically by simply 
examining the known relationship of the parents. As we have seen, information obtained 
from recent pedigrees often does not capture the total amount of relatedness present in 
samples with extensive historic parental relatedness. Secondly, due to small sample sizes 
as well as the use of a theoretical inbreeding coefficient F, the results of this approach 
vary depending on the choice of the regression model used. Finally, the approach 
assumes that the socio-economic backgrounds as well as care received with regard to 
complications that might arise during pregnancy is the same across groups with different 
relatedness structures. From long standing cohort studies in the UK(43) we know that 
communities with more historic cousin marriage practices also have higher levels of 
health deprivation and education, which may have a significant impact on the birth 
outcome. 
To minimize these limitations, we carried out a modern version of this approach by 
examining a dataset of 13776 mothers from the BiB cohort for which we had pregnancy 
outcomes. This dataset is particularly suited to this approach due to its large sample size 
from a single long-standing study in Bradford, UK. All of the mothers presented to the 
same maternity ward during their pregnancies and received standardised information on 
pre- and post-natal care. However the major difference from previous studies using this 
approach is that we had a direct DNA based estimate of the distribution of autozygosity 
(which we used in place of the the inbreeding coefficient) as a function of self-stated 
parental relatedness in this community from fig. S4A. We chose to remove pregnancies 
with the birth of more than one child to further remove bias. 
We calculated the Survivability (S) as the fraction of pregnancies that resulted in a 
healthy offspring surviving to at least one year of human life and carried out a weighted 
least squares regression as first described by Morton et al.(42) to estimate the coefficients 
and standard errors of the A and B terms in their model. In fig. 2C, we report our 
estimates, as well as those obtained from other previously reported studies(7, 8). The 
results obtained for A and B are 0.004970 (weighted least squares regression, SE 
0.001135, P=0.02205) and 0.22711 (SE 0.03745, P=0.00902) respectively. So as to be 
conservative with our results using this approach across all datasets, we choose to report 
the estimate of the number of recessive variants incompatible with healthy life in a 
human genome as B±SE.  
Along with these estimates based on epidemiological data, we also obtain a direct 
estimate of the number of recessive lethal variants based on the suppression of 
homozygote genotypes (as described above). For each allele frequency, we calculated the 
number of variants that are depleted compared to the neutral expectation of synonymous 
variants. We then take a weighted sum with the allele frequency to get the total number 
of LOF variants (not sites) that are expected to be incompatible with adult life across 
3,222 individuals. Standard errors are computed by a block jack-knife across individuals. 
As these variants are found in all 3,222 individuals we take the average to obtain an 
estimate for the number of heterozygous variants carried by a single individual that 
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would be lethal or result in severe disease if homozygosed. In fig. 2C, we also include 
another recent direct estimate for a similar measure using recessive disease pedigrees(44). 
 
 
Analysis of LOF load in different population cohorts and relation to demographic 
structure  
We carried out a comparative analysis of variants at functional loci and examined 
the mutational burden of LOF variants as identified by annotation between populations. 
To obtain a comparative dataset to use for the analysis, we obtained calls for worldwide 
populations from the 1000 Genomes Project phase 3 and restricted analysis to the same 
exome bait regions as our dataset and ran our annotation pipeline using the same settings 
as described earlier. We then annotated ancestral and derived alleles using Ensembl 
Compara’s 8 primates EPO alignment (http://www.ensembl.org/info/genome/compara/).  
We calculated a statistic described in (40, 45) which compares two populations, 
given a particular category of sites, in terms of the number of derived alleles found at 
sites within that category in one population rather than the other. The rationale behind the 
statistic is to compare the haploid load of mutations of a particular class in one population 
versus another. If the mutation rate per year is identical in both populations after the two 
populations have diverged and have undergone different demographic patterns, then the 
difference in the haploid mutational load has to have occurred due to selection. To 
aggregate information across multiple individuals, we use observed derived allele 
frequencies in each population and compute the statistic as follows. At each site i we 
write the observed derived allele frequency in population A as fAi = dAi / nAi , where nAi is 
the total number of alleles called there in population A and dAi is the number of derived 
alleles called. Similarly we define fBi in population B. Then if C is a particular category of 
protein-coding sites and S a set of synonymous sites, we define 
 !!,! ! =  !!!(1− !!!)!∈! !!!(1− !!!)!∈!  
 
as a measure of the relative number of derived alleles found more often in 
population A compared to population B. We then define the ratio  
 
RA/B = L A/B (C)/ LA/B(S), 
 
normalising by the value over putatively neutral synonymous sites, to mitigate any 
population-specific differences in overall mutation rate, as well as population-specific 
reference biases and any calling biases between our dataset and those from the 1000 
Genomes. This is akin to the approaches in (40, 45) where biases to do with branch 
shortening and deamination errors between ancient and modern genomes are mitigated. 
Estimates of the variance in RA/B were obtained using 100 block jackknifes on the set of 
sites in C.  
 Using our definition of LOF variants we then compared the value of RA/B in the 
1000 Genomes Project cohort and our dataset to look for differences in historic selection 
for variants of this specific class. Fig. 2D shows RA/B for LOF variants found in one 
population as a comparison with that from an outbred European ancestry population, 
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CEU. In most populations there is no significant difference. However, in the Finnish 
population sample (FIN), which underwent a severe bottleneck, we see significant 
differences compared to many other populations (Table S6). Our population (BB in fig. 
2D), which unlike FIN has a high heterozygosity so shows no evidence of a comparable 
bottleneck, shows a similar reduction in RA/B to FIN. We conclude that the reduction in 
load of severely deleterious mutations caused by homozygosing arising from endogamy 
in the BB population has been comparable to that arising from increased homozygosity 
during the bottleneck in the FIN population. We note that the CHS population from rural 
Southern China also has an increased RA/B  value without a decrease in heterozygosity, 
indicating that it may also have been subject to historical endogamy. The relatively high 
value of RA/B for the GBR population may be a consequence of one third of its samples 
coming from Orkney, a small island archipelago north of Scotland with a small long term 
endogamous population. 
 
 
Comparative genomics, human versus mouse 
 In order to understand the accuracy with which mouse models reflect human 
phenotype, we compared 215 genes with rhLOF in our dataset to mouse gene knockout 
data, requiring an exact 1:1 mouse:human gene ortholog. We removed genes with i) a one 
to many, or a many to one cross-species mapping; ii) removed genes where the human 
ortholog also has an OMIM annotation; iii) considered a mouse gene essential if in any 
strain or experiment reported in the Jackson Labs Mouse Genome Informatics 
Mammalian Phenotype database that there was a lethal phenotype observed. Of these, 
there were 52 genes where a lethal mouse phenotype had been reported on at least one 
genetic background. Properties of genes essential in mouse but not in humans showed no 
significant differences to those non-essential in both species across protein divergence 
(dN/dS), number of gene duplications in humans since species divergence, and gene 
expression (fig. S6) (all data downloaded from Ensembl BioMart).  
 
 
Druggability and clinical approval analysis 
We annotated genes with LOF variants with information concerning potential 
druggability – that is the potential for modulation of the protein target by a water-soluble 
small molecule drug. Druggable proteins usually contain a defined binding pocket or 
active site, which could act as a site of action (pharmacophore) for an orally bioavailable 
small molecule drug. We grouped proteins into four druggability classes, based on a 
collation of complementary published annotations of the potentially druggable genome 
and publically available databases of small molecules in the drug gene interaction 
database ((DGIDB); http://dgidb.genome.wustl.edu/; (v1.72). Targets in class D1 have a 
known drug recorded in dgidb; class D2 have small molecule tools recorded in CHEMBL 
(www.ebi.ac.uk/chembl) which may be in current development within pharmaceutical 
companies, and could be used as tools in animal and cellular models; class 3 are 
homologous to class 1 or class 2 targets described in several druggability publications 
collated in DGIDB; class 4 are predicted to contain a potentially druggable 
pharmacophore based on de novo structure-based druggability prediction using the 
dogsitescorer tool(46) (dogsite.zbh.uni-hamburg.de). 
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A protein can be considered a potential biopharmaceutical target if it is present in 
the cell membrane or extracellular space. Consequently we designated a protein as a 
biopharmaceutical target if it was reported to be extracellular or transmembrane in the 
Gene Ontology location category(47).  
We compared the ultimate success or failure of drug development for targets 
contained within the different LOF gene datasets using a recently published dataset of 
drug development outcomes for 19,085 target-indication 
pairs(11)(citeline.com/products/pharmaprojects/). We used a chi-squared test to evaluate 
differences in the ultimate EU/US approval rate for targets with observed LOF variants, 
compared to background information target-indication pair approval. 
 
 
Protein-protein interaction network analysis 
Collections of genes with loss of function (LOF) and gain of function (GOF) 
variants (table S4) were compared against a genome wide background of molecular 
interactions derived from the STRING database (string-db.org/). Interactions were 
organised into seven categories, Binding, Reaction, Activation, Expression, Catalysis, 
Post Translational Modification and All Interactions. The distribution of interactions 
were observed to be non-normal in most cases, probably due to missing data. We 
therefore compared the distributions of interactions between gene collections using a 
non-parametric Kruskal-Wallis test to obtain a p-value (R, http://www.r-project.org/). 
Low medians were seen across several of the seven interaction groups, therefore 5% and 
95% quantiles were also reported in addition to median values for each group. 
 
 
Sanger sequencing validation 
Previous work suggests that LOF variants might be enriched for sequencing 
errors(1). We recalled 19 subjects for validation: 12 because of a rhLOF genotype in a 
highly expressed blood gene (for use in RNA expression in blood studies), and 7 with 
diverse genes of potential interest. Of the 37 homozygous LOF genotypes in these 
subjects, we validated 35 rhLOF genotypes (2 could not be assayed) using a different 
method (Sanger dideoxy sequencing) in these independent samples (table S1). 
Sanger sequencing was performed on PCR products using an Applied Biosystems 
(Waltham, USA) 3730xl DNA analyser and big dye terminator 3.1 cycle chemistry. We 
sequenced all samples with rare variant allele genotypes, and a control sample, for the 
sites selected. 
 
 
Western blot and RNA expression validation 
Selected subjects were recalled for a further blood sample. Whole blood was 
preserved for RNA immediately upon venesection using PAXgene system (Qiagen, 
Venio, The Netherlands). Heparinized whole blood for protein assays was 
stored/transported at room temperature overnight and peripheral blood mononuclear cells 
were isolated by density gradient centrifugation with Lymphoprep (Stemcell 
Technologies, Vancouver, Canada). 
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Peripheral blood mononuclear cells were lysed using CelLytic M plus protease 
inhibitor (Sigma-Aldrich, St. Louis, USA). Cell extracts were quantified by BCA (Pierce, 
Waltham, USA) and stored at -80°C till required. 2-10ug protein/lane were run on either 
4-12% Tris Glycine or 10-20% Tricine Novex pre-cast gels (Life Technologies, 
Waltham, USA). Gel type used was determined by predicted protein size, specifically 
DPYD Tris-Gly gel 2ug; GCA Tricine gel 7.5ug; LSP1 Tris-Gly gel 3ug; SAMD9 Tris-
Gly gel 10ug and MSRA Tricine gel 10ug. Gel electrophoresis and transfer to Novex 
0.45µm PVDF membranes (Life Technologies) were done using the XCell surelock 
system (Life Technologies). Membranes were incubated with antibody at 4°C overnight 
before development using Fast Western SuperSignal West Pico kit (Pierce) and imaged 
using the hyperprocessor (Amersham Pharmacia Biotech, Little Chalfont, UK) with CL-
Xposure Film (Life Technologies). Membranes were stripped with Restore 
(ThermoScientific, Waltham USA) and reprobed with antibody against α-tubulin (α-tub, 
Abcam, Cambridge, UK) as loading control. 
RNA was extracted using PAXgene Blood RNA kit (Qiagen), quantified by 
NanoDrop 8000 UV-Vis Spectrophotometer (Thermo-Scientific) and Bioanalyser 
(Agilent). 250ng total RNA per sample was labelled with the Illumina total prep RNA 
amplification kit (Ambion, Waltham, USA), and 750ng of labelled sample then 
hybridised to Illumina HumanHT-12v4 Expression BeadChip according to manufacturers 
instructions. Quantile-quantile normalisation and analysis was performed using Illumina 
GenomeStudio. 
For a subset of genes known to be expressed in blood we observed the absence of 
protein on western blots using whole blood samples for 5 rhLOF genotypes (LSP1, 
DPYD, GCA, SAMD9, MSRA), weak protein (EMR2); and/or very low RNA expression 
compared to other samples for 6 rhLOF genotypes (LSP1, SLC27A3, GCA, SAMD9, 
MSRA, EMR2)(fig. S1). Extensive validation of LOF variants has been described 
elsewhere using RNA sequencing(3, 48). 
 
 
Manual annotation of rhLOF variants. 
For each genotype we manually reviewed final bam sequences in the IGV viewer 
2.3.59 (short read sequence data) for the rhLOF individual of interest, and 2 or more 
control subjects. We specifically looked for other nearby indels that would restore 
reading frame for rhLOF frameshift indels, and for adjacent variants that would eliminate 
stop codons, in addition to suspicious read alignment anomalies. We then examined the 
variant position in the UCSC genome browser, and in the ExAC browser, to look for 
potential issues with transcript and/or exon annotation that were missed by automated 
annotation with the LOFTEE tool. We reviewed rhLOF variants in annotated but non-
conserved, alternative reading frames than the canonical exon. Splice variants in the last 
exon or 3’UTR, as well as ones with a nearby frame-restoring potential splice site, were 
also considered as suspect on the grounds that they were likely not to impact protein 
function. Variants thought highly unlikely to cause LOF were removed and listed with 
reasons in Table S2. 
 
 
Comparison with a Mendelian disease database (OMIM) 
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 We downloaded the OMIM morbidmap (http://www.omim.org/downloads on 12 
May 2015), excluded records with “?” (unconfirmed or possibly spurious mappings) or 
“{}” (susceptibility to multifactorial diseases or infection) or “[]” (non-diseases that lead 
to apparently abnormal laboratory test values) annotation, included only records with 
“(3)” (molecular basis of the disorder is known) annotation and compared to our rhLOF 
gene list. We next selected only those genes with reported autosomal recessive 
inheritance (including those with multiple inheritance patterns) in OMIM. 
We note that our study has an ascertainment difference compared to much of the 
Mendelian disease literature in that subjects were recruited as relatively healthy adults 
rather than patients with severe and young-onset diseases (and often from multiply 
affected families). We also recognize that health record analysis differs from phenotyping 
with prior knowledge of genotype. 
Comments (columns in Table S3) were provided by independent review of the 
published phenotype-genotype associations and genome annotations by three clinical 
geneticists (AODL, ERM, RT), a clinician (DAvH) and a rare disease researcher 
(DMcA). Of the 38 individuals in Table S3 with rhLOF genotypes in OMIM recessive 
genetic diseases as identified above, 6 have compatible entries and 3 are partially 
compatible. Of the remaining 29 individuals, 12 have comments on the genotype-
phenotype association, and 8 have comments on the genomic annotation, with 1 having 
comments on both. Our review did not identify any possible reasons for absence of 
genotype-phenotype association for 9 individuals.  
 
 
Primary healthcare records of Born In Bradford (BiB) subjects 
All citizens of England are offered primary healthcare that is free at the point of use 
at general practices. Most practices have long used electronic health record (EHR) 
systems for the recording of diagnoses, symptoms, signs, according to the hierarchical 
system devised by Read (which maps to the internationally used SNOMED-CT) as well 
as prescriptions and test results. Structured primary care EHRs were obtained (and 
linked) for BiB participants registered with General Practitioner (GP) surgeries that use 
the TPP SystmOne platform. SystmOne has 100% coverage in Bradford and high 
coverage in surrounding areas. Records were extracted when the national unique health 
identifier (NHS number), surname, date of birth and gender were an exact match in 
SystmOne. From the full BiB cohort of 12450 mothers, 12333 (99.1%) were matched to 
their primary care records. Records were obtained from 18 months prior to study 
recruitment (Sep 2005 to Jun 2009), until end of November 2014, or until the participant 
died or withdrew from the cohort study if sooner. Total loss due to deaths, patients 
transferring to non-SystmOne practices, and withdrawing from the study, amounts to 0.4 
years per person, with records available for 6.9 years per person, from a possible 
maximum 7.3 years per person. Of 2162 exome sequenced individuals available for 
analysis, 2145 (99.2%) had matched GP records. 
For selected individuals with LOF variants of interest we also obtained lifetime 
electronic health records from SystmOne, and manually correlated Read codes with 
reported genotype-clinical phenotype associations in OMIM.  
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Primary healthcare record prescription- and consultation-rate analysis 
Using the primary healthcare records of BiB subjects, we performed a prescription 
rate analysis, assessing all classes of prescribed medicines, irrespective of indication. 
Drug prescriptions are captured in the primary care extract using 10-digit British National 
Formulary (BNF) IDs. Published data show a count of unique BNF chapter headings in a 
patient’s record can predict mortality and consultation rate(17). 10-digit BNF ID was 
truncated to a 4-digit chapter heading (the first two digits describe the organ system (e.g. 
cardiovascular), the second 2 digits the drug class (e.g. angiotensin converting enzyme 
inhibitors)), then distinct values per person were counted, so that multiple drug issues 
from the same BNF drug class were only counted once. 
We calculated Consultation rate as clinical consultations per person year, using the 
formula 365 * (NClinicalConsultationDays / DaysInSystem). A consultation event in 
SystmOne is an abstract event logged by the application when data is entered by a user. 
To avoid over-counting due to use of multiple SystmOne client sessions in one patient 
visit, days on which at least one consultation event occurred were counted 
(NClinicalConsultationDays), with the following criteria:  Include consultation events 
entered in a general practice setting; Include where the staff member role is GP/doctor or 
nurse; Include where consultation type is “Clinical”; Include where consultation method 
indicates face to face, telephone, home visit or unrecorded, but exclude others. The 
number of days per person transmitting GP data was derived from the SystmOne patient 
registration history. The extract begins 18 months prior to participant recruitment to the 
study. It ends (a) at end of November 2014, or (b) when the person withdraws from the 
study or (c) at death, whichever is earliest. A person can also transfer out of the system 
by registering with a non-SystmOne practice. These transfers out and back in were 
obtained from the SystmOne patient registration history, and the total number of days in 
the system per person was counted (DaysInSystem).  
DaysInSystem was also used as a covariate in adjusted models, except where 
consultation rate was also in the model, as consultation rate already includes this 
component. Patient age is also used as a covariate in adjusted models, computed as age in 
years at end of last SystmOne GP registration period. Deprivation has been shown to 
predict GP consultation rate(49). Conventional measures of deprivation may lack validity 
across ethnic groups due to cultural differences in economic priorities and 
opportunities(50), whereas education has been shown to be effective in capturing 
variation in socio-economic position (SEP) across UK ethnic groups. The covariate 
education, with international qualifications equivalised based on UK NARIC 
[http://ecctis.co.uk/naric/ accessed 13 Feb 2015], was included in adjusted models as a 
marker for deprivation. 
    The effect of LOF genotypes on prescribing and consultation rate was examined 
by logistic regression using Stata v13. Patient age, education and days in the system were 
covariates for adjustment for all analyses. For consultation rate analysis, we also used a 
measure of mother’s education level as the best BiB individual-level marker for 
deprivation.  
A small proportion of participants were in the system and providing data for a very 
short period that may not be sufficient to detect differences in disease burden. By way of 
sensitivity analysis, the above analyses were repeated only including patients who 
provided >5 person years of GP data (n=2020). Some authors have noted that individuals 
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at the same level of education are not necessarily comparable in terms of socioeconomic 
(SES), and that multiple SES indicators should be used(51). Previous work in the BiB 
cohort has shown that SES variation within Pakistani ethnicity participants is captured by 
education, receipt of means tested benefits, material deprivation, subjective poverty and 
employment status(52). A third set of sensitivity analyses included these multiple SES 
indicators. None of the sensitivity analyses described here indicated conclusions that 
differed from the main analyses. 
In addition to the primary rhLOF versus no rhLOF analysis (main text), we 
performed additional analyses in selected subgroups. We did not find association with 
prescription rate (logistic regression OR 1.006, 95% CI 0.966 - 1.045) or consultation 
rate (OR 1.029, 95% CI 0.964 - 1.090) in individuals (n=53) with rhLOF in OMIM 
confirmed recessive disease genes compared to individuals without rhLOF; nor on 
prescription rate (OR 1.005, 95% CI 0.968 - 1.043) or consultation rate (OR 1.038, 95% 
CI 0.978 - 1.094) in individuals (n=58) with rhLOF in orthologs of mouse knockout 
lethal genes. Findings were unchanged in additional adjusted analyses including age, 
education, duration of available data, and autozygosity. 
 
 
Analysis of a subject with a predicted PRDM9 knockout 
The mechanism behind the localization and regulation of meiotic recombination in 
humans and other mammals are of considerable interest. Much research has been 
focussed on understanding the role of a single rapidly evolving gene, PR domain-
containing 9 (PRDM9) in the molecular control of the distribution of meiotic double 
stranded breaks (DSBs) in mammals(53). Through the use of population based genome-
wide analyses, bulk sperm sequencing as well as genome editing in model organisms, 
meiotic DSB sites have been characterised at high resolution.  
Recent efforts have focused on understanding the patterns of recombination in 
species lacking PRDM9(54, 55) as well as mouse Prdm9 knockouts(22). These results 
suggest that in the absence of PRDM9 to localize breakpoints, most recombination is 
initiated at promoters and at other sites of PRDM9-independent H3K4 trimethylation. In 
humans, there has been extensive evidence to suggest that PRDM9 initiates and localises 
DSBs(56, 57) and is a major determinant of hotspots. However, insights into its 
essentiality as well as direct functional studies in-vivo in humans have not been carried 
out. Here, we identified as part of our study an individual containing a homozygous 
knockout in the PRDM9 gene, within a long autozygous region. We also studied one of 
three children (others in the family did not consent to research). We performed further 
experiments to define the recombination landscape in this family, and compared them to 
control data from a mother/child duo NA12878/NA12882 from a heavily studied three 
generation CEPH pedigree. NA12878 is homozygous for PRDM9-A, the most common 
allele of PRDM9. 
 
Validation of genotype and functional validation 
We examined a pileup of the exome sequencing reads for the variant as well as 
standard Sanger dideoxy-sequencing validation of the variant to confirm the quality of 
the genotype call  (fig. S7A,B). We also observed 10 additional (not closely related) 
individuals in our study population to be heterozygous at this variant. Heterozygote 
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variants (but no non-reference homozygotes) at this genotype were also observed in 
ExAC (http://exac.broadinstitute.org/variant/5-23524525-C-T). No homozygotes for any 
other PRDM9 LOF variants were observed in ExAC. We carried out careful manual 
annotation of the variant to ensure that the variant would result in a homozygous 
knockout of the gene, as described earlier. 
 
Cell line studies 
No primary cell lines or immortalised human cell lines stably expressing PRDM9 
were available, as PRDM9 is specifically expressed only at meiosis. We therefore 
performed site directed mutagenesis to generate the chr5:23524525 T allele using the 
QuikChange II mutagenesis kit (Agilent Technologies) and full-length PRDM9 cDNA 
cloned into the pCEP4 expression plasmid as described(20), and confirmed the expected 
allele and insert by sequencing. We transfected the plasmid into HEK293 cell lines as 
described(20), and assayed protein by western blot using anti-FLAG M2 (Sigma-
Aldrich), anti-H3 (EMD Millipore (Billerica, USA), 06-755), and anti-H3K4me3 (EMD 
Millipore, 07-473). Chromatin Immunoprecipitation and qPCR at 5A and 22A hotspots in 
HEK293 cells was performed as described using anti-H3K4me3(20). 
 
Illumina HiSeq X Ten whole genome sequencing 
Whole genome sequencing data for the PRDM9 minus duo was carried out by 
extracting DNA as described earlier. A single library (650 base pair inserts) was 
constructed for each sample. The libraries were multiplexed and sequenced across several 
lanes on the Illumina HiSeq X platform (paired-end sequencing, 151 cycles). Variant 
calling and filtering were carried out using the approaches described earlier. 
 
10XGenomics long range Gemcode molecular phasing 
The 10X Genomics (Pleasanton, USA) GemCode reagent delivery system partitions 
long DNA molecules (including DNA >100 kb) and prepares sequencing libraries in 
parallel across the partitions such that all fragments produced within a partition share a 
common barcode. A simple workflow combines large partition numbers with a massively 
diverse barcode library to generate >100,000 barcode containing partitions. Libraries on 
the mother and child were sequenced on an Illumina HiSeq 2500 instrument in Rapid 
Run mode. The GemCode Long Ranger Software maps short read data to original long 
molecules using the barcodes provided by the reagent delivery system, thus providing 
long range phasing information. 
The DNA samples available for the PRDM9 duo, whilst of adequately high 
molecular weight for most genomics applications, were more fragmented than for the 
Coriell (Camden, USA) reference samples NA12878 and NA12882 (Table S7). 
Nonetheless, >90% of SNPs could be phased in each of the four samples. Unlike, e.g. 
detection of structural variants, identification of recombination breakpoints is less 
sensitive to the length of phased segments. 
 
Obtaining recombination breakpoints using phased parent-child duos 
We identify recombination crossover sites in the maternal meiosis leading to the 
child’s genome using heterozygous sites in the mother and child that are informative 
about the transmitted chromosome. Of the possible allelic combinations of the mother 
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and child at each site (Table S8) four combinations are informative if only the mother is 
phased while eight are informative if both the mother and child are phased.  To avoid 
false positives due to genotype and phasing errors, we used this information in a series of 
steps. 
Initially we only used phase information from the mother and considered bi-allelic 
SNPs that were of high quality (10XGenomics phase quality scores at maximum). Once 
we located candidate intervals we removed crossover intervals that lay within 300kb of 
each other. Then we carried out manual visualisation of the crossover locations in the 
10XGenomics Loupe browser to ensure that there were at least two informative SNPs on 
each side of a crossover that were of maximum quality. We then refined the crossover 
intervals using the child’s phasing where it was available and overlapped with the phase 
set of the mother (this was in >90% of cases in NA12878 duo and ~70% in the PRDM9 
duo), as well as considering sites where the phase quality was lower but was nevertheless 
consistent with the phased genotypes in the other sample of the duo.  This approach 
resulted in 42 crossovers in NA12878 / NA12882 duo with a mean crossover interval 
length of 16.2kb, and 37 crossovers in the PRDM9 duo with a mean crossover length of 
51.8 kb.  
As a validation of our method, we compared the crossovers inferred in the NA12878 
duo to a gold standard set derived independently for the same meiosis from segregation 
data across the complete three generation CEPH pedigree, all of whose members had 
been previously sequenced (58). This approach yielded a set of 53 crossovers with a 
mean interval length of 40.5kb.  40/42 (95%) of the crossovers inferred from the 10X 
Genomics phasing data overlap those from the pedigree based gold standard, signifying 
that our strategy identifies crossovers in parent-child duos with high specificity. 
 
Statistical analysis to infer recombination landscapes 
In order to compare the recombination landscape of the two samples, we utilized a 
method that has been previously described in several studies that have compared 
crossovers obtained from pedigree based studies with those from the fine scale 
recombination map(18, 59). Here, we seek to examine the PRDM9 hotspot usage 
phenotype by comparing the crossover events that we call using long range molecular 
phasing with those obtained from high-resolution maps of meiotic DSBs in individual 
human genomes(25). These are tightly coupled with crossover locations observed from 
population sequencing and linkage disequilibrium (LD) based methods but provide 
information on the localisation of DNA binding by PRDM9 at a much finer scale. For 
additional confirmation and to compare our results with those from these previous studies 
we also utilized 32,996 autosomal hotspot locations inferred from genome-wide Phase II 
HapMap LD data(57). 
The method estimates the proportion of crossovers (!) that occur in a set of 
predefined feature intervals. Care must be taken because we do not know the precise 
location of the crossover, only an interval (possibly large) within which it took place. We 
utilise the previously published method almost exactly as referenced above but describe it 
again here due to slight changes in implementation. We begin by obtaining the 
probability that crossover interval r overlaps a feature: 
P(r overlaps a feature) = !  + (1-!)P(r overlaps a feature by chance) 
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We estimated P(r overlaps a feature by chance) by randomly shifting the crossover r 
a normally-distributed distance (mean 0, std. deviation 200kb) 100 times and counting the 
fraction of these moves that result in the crossover r overlapping a feature (note that this 
probability differs for each crossover, due to the size of the interval containing r and the 
density of features in the local region). The likelihood of ! for a crossover r is !r P(r 
overlaps a feature) + (1-!r)(1-P(r  overlaps a feature)), where !r is an indicator variable 
that is 1 if r overlaps a feature and 0 if not. The likelihood of ! for the full set of 
crossovers is the product of the per-crossover likelihoods. 
  As in the previous references, the likelihood of ! for all crossovers localised to an 
interval smaller than 30kb was calculated over a range of values between 0 and 1 in 100 
steps and implemented using the NLM package in r. The 95% confidence interval of ! 
was considered to include all values of ! for which the log likelihood was within 2 units 
(the asymptotic cutoff) of the maximum log likelihood. Note that this estimation 
procedure naturally accounts for uncertainty in the location of LD hotspots and in the 
location of crossovers, as the overlap by chance is influenced by both the width of the 
estimated hotspots and the interval sizes in which we infer crossovers. 
We report in the main text point numbers for the 23 crossovers in the PRDM9- duo 
and 34 crossovers in the NA12878 duo localised to within 30kb.  When using all 37 
(respectively 42) crossovers we get consistent results: for the PRDM9 A Union DSB 
hotspots: NA12878 duo - 55.2% [2 log unit confidence interval 38%-71%], PRDM9- duo 
- 9.7% [0%-26%]; and for the LD based hotspots NA12878 - 72.1% [54%-86%], 
PRDM9- - 18.3% [2%-34%]. 
 
Examination of crossover overlap with GC rich regions, promoters or H3k4me3 
sites 
We obtained GC content, gene promoter and promoter flanking region information 
from Ensembl(39), and consolidated imputed data for narrow contiguous regions of 
enrichment (peaks) for H3K4Me3 ChIP-seq data for multiple cell types from the 
epigenomics roadmap project(60). Using the same approach as for overlap of our regions 
with PRDM9 hotspots we found no significant differences between the proportion of 
crossovers overlapping H3K4Me3 sites (NA12878 duo 4% [2 log unit confidence 
interval 0-8%], PRDM9 duo 5% [0-8%]), gene promoters (NA12878 duo 0% [0-4%], 
PRDM9 duo 0%[0-4%])  and their flanking regions, or in the GC content of 200kb of 
DNA (t-test P=0.64) from the middle position of each crossover interval.  	 	
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Fig. S1. 
RNA and protein level validation of predicted LOF genotypes. Left panels show protein 
expression from Western blot. Right panels show probe-level Illumina HT-12v4 RNA 
expression array data. Panels A,B,C,D,E show absent protein in the LOF sample as 
assessed by Western blot. Panel G shows low protein in the LOF sample. Panel F shows 
apparently normal protein (presuming the antibody is specific) but low RNA levels in the 
LOF sample. 				 	
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Fig. S2. 
DNA-determined heritage. Principal component analysis was performed on individuals 
from Phase 3 of the 1000 Genomes Project, with the current dataset mapped onto this 
reference. We defined a polygon to include samples that were clustered together with the 
1000 Genomes Project Pakistani population. Legends: BB - Birmingham and Born In 
Bradford; others - 1000 Genomes Project ethnic groups. PCA polygon (in black) refers to 
the subset of samples retained in the BB dataset for further analysis. 	 	
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Fig. S3. 
Estimates of number of rare homozygous knockout genes seen in larger cohorts (blue 
circles), and number of rare homozygous knockout genes with more than 4 individuals 
(orange circles). 		
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Fig. S4. 
Analysis of autozygosity in populations. (A) Self-stated vs genetic autozygosity for 
individuals from Born In Bradford. Distribution of total length of genome in autozygous 
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stretches shown in boxplots, with individuals for whom no data was available indicated in 
the ‘Don’t know’ column. Genetic autozygosity, declines with self-stated parental 
relatedness and reflects theoretical expectations. (B) Levels of autozygosity observed 
across the genome. Number of individuals autozygous at a site in the protein coding 
sections of the genome (blue circles) across positions on chromosome 1 (shown as a 
representative example) on the x-axis. Inset in orange circles is a Q-Q plot of the 
theoretical expectation of the distribution, and shows normality of the data. 		 	
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Fig. S5. 
Using heterozygous calls within an autozygous section as a measure of variant quality 
control. Total number of discovered heterozygous sites in 3,222 individuals as a function 
of sites that were heterozygous within an autozygous block (x-axis) across individual 
chromosomes (colored circles on left panel) and summed across the genome (blue circles 
on right panel). Total number of sites overall is represented by the size of circle. Labels 
on each point represent in order: the VQSR false positive threshold reflecting the 
percentage of true positive sites left; (right panel only) the fraction of total sites left at 
that threshold, the mean number of hets per person and the number of false heterozygote 
sites left.  				 	
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Fig. S6. 
Mouse Human Orthologs. Properties of genes essential in mouse but not in humans 
(HnMe), compared with those non-essential in both species (HnMn) across protein 
sequence divergence (dN/dS), number of gene duplications in humans since species 
divergence and gene expression show no significant differences. 		 	
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Fig. S7. 
Genomic analysis of PRDM9 rhLOF mother and her child. (A) Exome sequencing reads 
showing PRDM9 chr5:23524525 C / T variant in a control (upper image, genotype CC) 
sample (upper), and in the mother (lower image, genotype TT). Images from the 
Integrated Genome Viewer. (B) Sanger dideoxy sequence traces of child (upper trace). 
This confirms the expected heterozygous genotype and germline transmission of this 
allele. Middle trace mother, bottom trace control sample. (C) Genomic map of 
autozygous (identical-by-descent) regions in the mother, showing position of the PRDM9 
rhLOF. 		 	
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Fig. S8. 
Expression of PRDM9 in HEK293 cells. FLAG-tagged PRDM9 constructs were 
expressed for 48h in HEK293 cells. (A) Upper panel: the expected protein sizes (full 
length 110.1kDa, R345Ter 43.2kDa) were confirmed on western blot. Middle panel: 
expression of mutant PRDM9 (R345Ter) does not increase global H3K4me3 indicating 
loss-of-function. Lower panel: histone H3 levels are similar across all samples. (B) 
R345Ter specifically disrupts PRDM9-dependent methylation at hotspots. ChIP for 
H3K4me3 after expression of PRDM9 in HEK293 cells followed by qPCR at two 
recombination hotspots (5A and 114) and PRDM9-independent promoter (GAPDH). 
Filled symbols: full length PRDM9, open symbols R345Ter. Lines indicate mean±SD.  
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GENE	 SEVERE IMPACT	 CHR	 POS 
(GRCh37)	 REF ALLELE	 ALT ALLELE	 VALIDATION (of rhLOF genotype)	
ANKRD33	 splice_acceptor	 12	 52282350	 A	 G	 yes	
BHMT2	 splice_acceptor	 5	 78379449	 A	 G	 yes	
BTN3A3	 stop_gained	 6	 26446011	 G	 A	 (unable to design 
primers / obtain 
clear PCR band)	
C1orf127	 stop_gained	 1	 11008613	 G	 A	 yes	
C1QTNF8	 stop_gained	 16	 1143912	 G	 T	 yes	
CALHM2	 frameshift	 10	 105209371	 CA	 C	 yes	
CD33	 frameshift	 19	 51738926	 TC	 T	 yes	
CDK15	 stop_gained	 2	 202744869	 C	 T	 yes	
CTB-133G6.1	 splice_donor	 19	 7437958	 G	 T	 yes	
CWH43	 frameshift	 4	 49034669	 CA	 C	 yes	
DPYD	 splice_donor	 1	 97915614	 C	 T	 yes	
EMR2	 frameshift	 19	 14863172	 AAG	 A	 yes	
FAM92B	 stop_gained	 16	 85133762	 G	 A	 yes	
FLG	 frameshift	 1	 152285076	 CACTG	 C	 (unable to design 
primers / obtain 
clear PCR band)	
GCA	 stop_gained	 2	 163215655	 C	 T	 yes	
GJB2	 stop_gained	 13	 20763490	 C	 T	 yes	
HTR2B	 stop_gained	 2	 231973941	 T	 A	 yes	
HTR2B	 stop_gained	 2	 231973941	 T	 A	 yes	
LIFR	 frameshift	 5	 38530726	 CA	 C	 yes	
LINC00935	 splice_donor	 12	 49121343	 G	 A	 yes	
LSP1	 stop_gained	 11	 1874388	 C	 A	 yes	
MICALCL	 frameshift	 11	 12316171	 C	 CA	 yes	
MSRA	 stop_gained	 8	 9912126	 C	 T	 yes	
MYO1A	 stop_gained	 12	 57437748	 G	 A	 yes	
MYO1A	 splice_acceptor	 12	 57424959	 C	 A	 yes	
PLD2	 splice_acceptor	 17	 4711568	 G	 A	 yes	
PRDM9	 stop_gained	 5	 23524525	 C	 T	 yes	
RP11-293M10.1	 frameshift	 14	 75705824	 CA	 C	 yes	
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RP11-552I14.1	 splice_donor	 12	 103558217	 T	 C	 yes	
SAMD9	 stop_gained	 7	 92732604	 G	 T	 yes	
SLC26A10	 frameshift	 12	 58016602	 AGCTGCCC
AGGATTCT
G	 A	 yes	
SLC27A3	 splice_donor	 1	 153750362	 G	 C	 yes	
TRDN	 stop_gained	 6	 123539855	 A	 T	 yes	
USP45	 stop_gained	 6	 99936089	 G	 C	 yes	
ZBBX	 splice_donor	 3	 167083673	 C	 G	 yes	
ZBTB24	 frameshift	 6	 109787512	 TAG	 T	 yes	
ZSCAN16	 stop_gained	 6	 28097384	 C	 T	 yes		
Table S1. 
Sanger sequencing validation of variants identified by exome sequencing. 	
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Gene 	 Number of Individuals 
with rhLOF	 Chr	 Pos	 REF allele	 ALT allele	 Comments	
C12orf57	 2	 12	 7053817	 TGGGTCAGACGCGGG
AAGGC	 T	 Frameshift not affecting splice site - error in Variant Effect Predictor 79.	
CLN3	 2	 16	 28499964	 G	 A	 LOF is relative to a misassigned reading frame for this transcript in GENCODE.	
DPM2	 1	 9	 130698730	 G	 A	 Alternate exon in GENCODE, not in RefSeq or UCSC annotation, possible 
misannotation.	
DTNBP1	 1	 6	 15524715	 G	 A	 LOF annotation for only 1 of 4 transcripts containing this variant, extends penultimate exon another 30 amino 
acids before stop codon, poorly 
conserved. Possible misannotation.	
GHRHR	 1	 7	 31009418	 AC	 A	 Variant not in canonical transcript (which has 3 upstream exons), variant is in non-conserved region of alternative 
transcripts, possible misannotation.	
LRTOMT	 2	 11	 71807767	 A	 C	 Only 2 of 12 GENCODE transcripts include this region as an exon, possible 
misannotation.	
POMGNT1	 2	 1	 46654912	 A	 T	 Canonical transcript is dubious - other transcripts are likely the proper frame, 
where this is a UTR splice variant.	
PUS1	 1	 12	 132416630	 A	 T	 LOF annotation for only 1 of 5 transcripts, other transcripts do not use the first exon containing the variant. 
Possible misannotation.	
NF1	 1	 17	 29706042	 G	 A	 Splice in UTR in all but 1 transcript, likely erroneous transcript.	
WWOX	 3	 16	 79245892	 GGGGCT	 G	 LOF annotation for only 1 of 5 long transcripts, likely misassigned reading frame for this transcript in GENCODE.		
Table S2. 
Variants in OMIM-disease genes erroneously described as LOF due to genome/transcript 
misannotation.
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Gene	 Chr	 Pos	 REF 
allele	 ALT allele	 OMIM entry	 Relevant Read codes (primary 
healthcare 
record)	 Is healthcare record compatible with OMIM 
phenotype?	
Additional 
Comments on 
OMIM genotype-
phenotype 
association	
Additional 
Comments on 
genome 
annotation	
AHI1	 6	 135726088	 CT	 C	 Joubert syndrome-3, 608629	 -	 No	 One report of C-
terminal SH3 
domain LOF 
variants being 
tolerated	
-	
AKR1D1	 7	 137792166	 AT	 A	 Bile acid synthesis defect, 
congenital, 2, 235555	 -	 No	 -	 -	
ALDH6A1	 14	 74533476	 G	 A	 Methylmalonate 
semialdehyde 
dehydrogenase deficiency, 
614105	 -	 No	 Whilst recessive, only missense mutations described. 
Reduced enzyme 
activity reported 
in one subject 
consistent with 
LOF.	
-	
ARMC4	 10	 28270472	 TTC	 T	 Ciliary dyskinesia, primary, 
23, 615451	 asthma	 Partial	 -	 -	
ATR	 3	 142178067	 A	 G	 Seckel syndrome 1, 210600	 -	 No	 Only two patients 
reported for 
autosomal 
recessive ATR 
related disease.	
-	
ATR	 3	 142178067	 A	 G	 Seckel syndrome 1, 210600	 -	 No	 Only two patients 
reported for 
autosomal 
recessive ATR 
related disease.	
-	
COL1A2	 7	 94043055	 GGTGA	 G	 Ehlers-Danlos syndrome, 
cardiac valvular form, 
225320	 -	 No	 Relatively few patients reported.	 Possibility splice site may be unaffected by 
variant.	
COL6A2	 21	 47549195	 CCT	 C	 Bethlem myopathy, 158810		
Ullrich congenital muscular 
-	 No	 -	 Variant only 
affects some of 
multiple 
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dystrophy 1	
254090	 transcripts, and is in short 
homopolymer.	
DCHS1	 11	 6662402	 G	 GTGT
GGTT	 Van Maldergem syndrome 1, 601390	 -	 No	 Single published report although 
multiple affected 
individuals with 
different variants.	
-	
DNAI2	 17	 72295871	 C	 T	 Ciliary dyskinesia, primary, 
9, with or without situs 
inversus, 612444	 allergic rhinitis, asthma, chronic sinusitis, chest 
infection [multiple 
entries], primary 
ciliary dyskinesia, 
situs inversus	
Yes	 -	 -	
DYSF	 2	 71788881	 G	 T	 Miyoshi muscular dystrophy 
1, 254130	 genetic syndrome, muscular 
dystrophy, ECG: 
Q-T interval 
abnormal	
Yes	 -	 -	
EXPH5	 11	 108381750	 AT	 A	 Epidermolysis bullosa, 
nonspecific, autosomal 
recessive, 615028	 -	 No	 -	 -	
FBXO7	 22	 32875119	 G	 C	 Parkinson disease 15, 
autosomal recessive, 
260300	 -	 No	 -	 Variant is in a single alternatively 
spliced transcript. 
Other variants 
are coding at this 
position, or start 
after this position.	
FLG	 1	 152285076	 CACTG	 C	 Ichthyosis vulgaris, 146700	 dermatitis, eczema	 Yes	 -	 -	
FLG	 1	 152276737	 TC	 T	 Ichthyosis vulgaris, 146700	 asthma, dermatitis, 
eczema	 Yes	 -	 -	
GJB2	 13	 20763490	 C	 T	 Deafness, autosomal 
recessive 1A, 220290	 telephone consultation 
[multiple entries. 
suggests adequate 
hearing ability]	
No	 This variant 
known to have 
variable 
expressivity	 -	
GJB4	 1	 35227241	 G	 A	 Erythrokeratodermia 
variabilis with erythema 
dermatitis NOS, 
rosacea	 Partial	 Most reports are of heterozygous -	
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gyratum repens, 133200	 variants 
(dominant), only 
one homozygous 
(recessive) 
patient 
described.	
GYS2	 12	 21713391	 G	 GA	 Glycogen storage disease 0, 
liver, 240600	 [normal liver function tests]	 No	 Mild/subclinical phenotypes 
reported.	 -	
LIFR	 5	 38530726	 CA	 C	 Stuve-Wiedemann 
syndrome/Schwartz-Jampel 
type 2 syndrome, 601559	 -	 No	 -	 Some transcripts have start sites downstream of 
variant in first 
exon.	
MYO3A	 10	 26315400	 C	 T	 Deafness, autosomal 
recessive 30, 607101	 hearing test normal	 No	 Variability reported in age of 
onset of hearing 
loss.	 -	
NEB	 2	 152544805	 C	 T	 Nemaline myopathy 2, 
autosomal recessive, 
256030	 -	 No	 -	 -	
NME8	 7	 37907302	 A	 G	 Ciliary dyskinesia, primary, 
6, 610852	 hayfever, asthma, rhinitis	 Partial	 Only single patient case 
report.	 Exon not used in all transcripts.	
NPC2	 14	 74947404	 C	 T	 Niemann-pick disease, type 
C2, 607625	 X-linked centronuclear 
myopathy [Note 
different type of 
myopathy in 
healthcare record 
to OMIM entry.]	
Yes	 -	 Nearby in-frame 
splice site 
available, which 
may rescue 
splicing.	
OPA3	 19	 46032442	 G	 A	 3-methylglutaconic aciduria, 
type III, 258501 	 -	 No	 Suggestion in literature that 
less deleterious 
alleles could 
present as later 
optic atrophy. 
This variant 
truncates ~41aa 
of 180aa gene.	
-	
PDE6A	 5	 149240535	 C	 CT	 Retinitis pigmentosa 43, 
613810	 -	 No	 -	 Splice acceptor site in last exon.	
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PLA2G7	 6	 46679232	 C	 T	 Platelet-activating factor 
acetylhydrolase deficiency, 
614278	 -	 No	 Variable penetrance (of asthma, 
thrombosis) 
reported in 
literature. Despite 
OMIM 
annotation, is 
more of a 
disease risk 
modifier than 
strong Mendelian 
phenotype.	
-	
PLA2G7	 6	 46679232	 C	 T	 Platelet-activating factor 
acetylhydrolase deficiency, 
614278	 -	 No	 Variable penetrance (of asthma, 
thrombosis) 
reported in 
literature. Despite 
OMIM 
annotation, is 
more of a 
disease risk 
modifier than 
strong Mendelian 
phenotype.	
-	
PNPLA1	 6	 36274148	 T	 A	 Ichthyosis, congenital, 
autosomal recessive 10, 
615024	 -	 No	 -	 -	
RDH5	 12	 56115279	 G	 A	 Fundus albipunctatus, 
136880	 -	 No	 -	 -	
SAG	 2	 234243675	 C	 T	 Oguchi disease-1, 258100	 -	 No	 -	 -	
SAMD9	 7	 92732604	 G	 T	 Tumoral calcinosis, familial, 
normophosphatemic, 
610455	 -	 No	 -	 -	
SLC24A1	 15	 65931948	 AC	 A	 Night blindness, congenital 
stationary (complete), 1D, 
autosomal recessive, 
613830	 no visual symptom	 No	 Published report from single large pedigree, although there is 
supportive 
mouse model.	
-	
SP110	 2	 231036485	 T	 A	 Hepatic venoocclusive -	 No	 -	 Variant is in a 
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disease with 
immunodeficiency, 235550	 conserved exon, although exon 
only used in one 
of multiple 
alternatively 
spliced 
transcripts.	
TMC8	 17	 76127762	 C	 CT	 Epidermodysplasia 
verruciformis, 226400	 -	 No	 -	 Possible alternative start 
site downstream 
of variant, which 
is in first exon.	
TRNT1	 3	 3188249	 T	 C	 Sideroblastic anemia with B-
cell immunodeficiency, 
periodic fevers, and 
developmental delay, 
616084	
[normal full blood 
count]	 No	 -	 Single alternatively 
spliced transcript. 
Non-conserved 
splice site in 
middle of exon in 
other transcripts, 
possible 
annotation error.	
TRPM1	 15	 31318399	 TC	 T	 Night blindness, congenital 
stationary (complete), 1C, 
autosomal recessive, 
613216	 electromyogram (EMG) abnormal, impaired vision	 Yes	 -	 -	
XDH	 2	 31625970	 G	 GC	 Xanthinuria, type I, 278300	 -	 No	 -	 -	
ZBTB24	 6	 109787512	 TAG	 T	 Immunodeficiency-
centromeric instability-facial 
anomalies syndrome-2, 
614069	 -	 No	 -	 -	
Table S3. 
Compatibility of primary healthcare records of Born In Bradford subjects with OMIM recessive genetic diseases for which they have 
rhLOF genotypes. OMIM autosomal recessive phenotypes only. Each row represents a sequenced individual (i.e. separate individuals 
if a gene name is present twice). Entries marked [ ] are our interpretation/summary of healthcare record codes. Unoconfirmed or 
possibly spurious OMIM genotype-phenotype associations, and clearly false genome annotations were previously filtered at the 
OMIM morbidmap analysis stage or in Table S2, respectively. The two additional comments columns provide further information 
relevant to the likelihood of true LOF genomic annotation and genotype-phenotype association 	
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 	 STRING	
Reference	
(n=15561)	 Born in Bradford 	LOF all (n=476)	 Decode	LOF all 	(n=3769)	 Decode	LOF “benign”	 (n=3530)	 Decode 	LOF “pathogenic” 	(n=416)	 Orphanet	GOF all	(n=106)	 Orphanet	LOF all	(n=458)	
Binding	
p-value,	median,		
[5th-95th	quantiles]	  	10, [0-139]	 9.3 x10-11	5.5, [0-61]	 6 x10-07	9, [0-115]	 2 x10-06	9, [0-106]	 0.0105	7, [0-271]	 2.8 x10-09	26, [2-152]	 0.0018	14, [0-95]	
Reaction	
p-value,	median,		
[5th-95th	quantiles]	  	0, [0-77]	 0.0047	0, [0-39]	 0.0152	0, [0-71]	 0.0019	0, [0-55]	 0.0134	0, [0-543]	 3 x10-06	0, [0-52]	 0.0499	0, [0-73]	
Activation	
p-value,	median,		
[5th-95th	quantiles]	  	0, [0-6]	 0.533	0, [0-4]	 3.9 x10-06	0, [0-4]	 1.9 x10-06	0, [0-4]	 0.3139	0, [0-4]	 1 x10-17	1, [0-44]	 3.3 x10-13	0, [0-11]	
Expression	
p-value,	median,		
[5th-95th	quantiles]	  	0, [0-8]	 0.3723	0, [0-6]	 3.6 x10-05	0, [0-5]	 4 x10-05	0, [0-5]	 0.0309	0, [0-4]	 1.7 x10-17	1, [0-45]	 1.8 x10-18	0, [0-23]	
Catalysis	
p-value,	median,		
[5th-95th	quantiles]	  	0, [0-9]	 0.0007	0, [0-1]	 0.0001	0, [0-4]	 0.0003	0, [0-4]	 0.019	0, [0-1]	 7.9 x10-08	0, [0-27]	 0.0001	0, [0-17]	
Post	Trans	Mod	
p-value,	median,		
[5th-95th	quantiles]	  	0, [0-6]	 0.002	0, [0-3]	 0.0051	0, [0-4]	 0.0119	0, [0-5]	 0.00135	0, [0-3]	 6.4 x10-27	1.5, [0-31]	 8.2 x10-05	0, [0-9]	
All	Interactions	
p-value,	median,		
[5th-95th	quantiles]	  	14, [0-211]	 3.4 x10-09	7, [0-98]	 4.8 x10-08	11, [0-166]	 4.7 x10-08	11, [0-155]	 0.0438	10, [0-815]	 2 x10-12	47.5, [4-305]	 1.1 x10-06	24, [1-180]		
Table S4. 
A systematic evaluation of the degree of protein-protein interaction in genes carrying Loss of Function (LOF) variants. The following 
gene sets were compared against genome-wide interactions in the STRING dataset: “Born in Bradford LOF all” (n=476), representing 
a non-redundant list of genes with observed LOF variants observed in this study in the Born in Bradford cohort. “Decode LOF all” 
(n=3769), represents all genes with LOF variants in an Icelandic sample(3), these genes are further divided into two subgroups 
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“Decode LOF “benign”” (n=3530), a subset of genes with LOF variants identified in healthy subjects and “Decode LOF 
“pathogenic”” (n=416), a subset of genes with LOF variants identified in subjects with 1 or more offspring that died before age 15. 
The final two gene sets, “Orphanet GOF all” (n=106) and “Orphanet LOF all” (n=458), represent genes with pathogenic Mendelian 
gain of function and loss of function variants respectively reported in the Orphanet rare disease catalogue (www.orpha.net). 
Bonferroni corrected (42 comparisons) P values <0.0012 shown in bold (Kruskal-Wallis test). 		 	
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Table S5. 
Pairwise genotypes for duplicate samples across evaluated individuals and regions. Pairwise genotypes (Ref, Het, Alt) across 176 
duplicate pairs that were evaluated genome wide and just within the autozygous sections along with those from 176 unrelated 
(random) pairs. VQSR true positive percentage reflect the portion of true positive sites left (at VQSR= 90, 99, 100). 		 	
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Table S6. 
Pairwise RA,B values across different populations. Numbers in bold reflect the pairwise RA,B values for LOF variants normalized by the 
synonymous variant counts while the jacknife standard errors are shown in brackets. Highlighted in blue are comparisons that are at 
least 2 standard errors away from 1 (neutral expectation) and in orange are comparisons that are 3 standard errors away. 				 	
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	 SNPS phased	 DNA in 
molecules >20kb	
GEMs detected	 N50 phase block	 Mean depth	
NA12878	 96.2%	 89.1%	 247924	 16674432 bp	 33.9 X	
NA12882	 97.8%	 85.4%	 245880	 9346942 bp	 28.2 X	
PRDM9 knockout 
mother	 92.6%	 70.4%	 235515	 586148 bp	 29.9 X	
Her son	 90.7%	 27.9%	 223067	 157393 bp	 26.2 X		
Table S7. 
10XGenomics summary statistics on sequenced samples. 		 	
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		 Allelic combinations	
Mother 1	 0	 0	 1	 1	 1	 1	 0	 0	 0	 0	 1	 1	 1	 1	 0	 0	
Mother 2	 0	 0	 1	 1	 0	 0	 1	 1	 1	 1	 0	 0	 1	 1	 0	 0	
Child mat	 0	 0	 1	 1	 0	 0	 1	 1	 0	 0	 1	 1	 1	 1	 0	 0	
Child pat	 0	 1	 0	 1	 0	 1	 0	 1	 0	 1	 0	 1	 0	 1	 0	 1		
Table S8. 
Allelic combinations of sites informative about recombination in mother child duos. Numbers show the different alleles (0-reference, 
1-alternate) seen in the parent and child for bi-allelic sites. The first 8 configurations show transmission of the chromosome Mother 2 
while the next 8 show transmission of chromosome Mother 1. Sites that are informative when only the mother is phased are shown in 
orange, while additional sites that are informative when the child is also phased so as to identify the maternal chromosome are shown 
in yellow.  
 
